Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "renal"

158 News Found

Lupin receives USFDA approval for Bumetanide Injection
Drug Approval | September 19, 2024

Lupin receives USFDA approval for Bumetanide Injection

Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.


Novartis and Versant to form biotech venture Borealis Biosciences
Biotech | August 23, 2024

Novartis and Versant to form biotech venture Borealis Biosciences

Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company


Sun Pharma introduces STARIZO in India for skin infections
News | August 23, 2024

Sun Pharma introduces STARIZO in India for skin infections

Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India


Nephro Care India reports 86.07% jump in PAT at Rs 4.41 crore during FY 23-24
News | August 23, 2024

Nephro Care India reports 86.07% jump in PAT at Rs 4.41 crore during FY 23-24

Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line


Pfizer announces results of ABRYSVO for RSV in immunocompromised adults
Clinical Trials | August 13, 2024

Pfizer announces results of ABRYSVO for RSV in immunocompromised adults

These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV


American Oncology Institute (AOI) Nagpur conducts two consecutive successful bone marrow transplants
News | July 31, 2024

American Oncology Institute (AOI) Nagpur conducts two consecutive successful bone marrow transplants

Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection


Nephro Care India lists at 90% premium
News | July 06, 2024

Nephro Care India lists at 90% premium

NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90


Biogen completes acquisition of HI-Bio
News | July 06, 2024

Biogen completes acquisition of HI-Bio

Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study